TOP BAR MENU Investors & Media Careers Connect Healthcare Professionals Our DNA How We Translate Science For Patients COVID-19 BioNTech HCP Hub This site is intended for Global Healthcare Professionals The following website is intended for healthcare professionals only. Please select one of the following options: I am a Healthcare Professional SELECT I am NOT a Healthcare Professional SELECT Welcome to BioNTech’s information center for healthcare professionals Authorization status of the COVID-19 mRNA Vaccine (BNT162b2) In the EU and Switzerland, BNT162b2 received Conditional Marketing Authorizations under the name COMIRNATY®. Following recommendation of the European Medicine Agency (EMA), COMIRNATY® (COVID-19 mRNA Vaccine) has been granted conditional marketing authorization by the European Commission for active immunization to prevent COVID-19 caused by SARS-COV-2 virus, in individuals 16 years of age and older. For the EMA SmPC, please visit the download section on the EMA website. In the U.S., BNT162b2 is authorized under an Emergency Use Authorization (EUA) as "Pfizer-BioNTech COVID-19 Vaccine". The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com. In the UK, BNT162b2 is authorized under a temporary authorization for emergency supply under the name "COVID-19 mRNA Vaccine BNT162b2". Additional rolling submissions have been initiated across the globe including Australia and Japan. Applications to other regulatory agencies around the world are planned to be submitted. Please check the approval status in your respective country. For further country specific prescribing information, please visit www.cvdvaccine.com. Indication and Usage The COVID-19 mRNA Vaccine (BNT162b2) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older. The use of the COVID-19 mRNA Vaccine (BNT162b2) should be in accordance with official guidance. Additional Safety Monitoring This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions: Email: medinfo@biontech.de Phone: +49 6131 9084-0 Information on how to report adverse events can be found at Medical Information Center. BioNTech MIC Find more information in our Medical Information Center GO TO SITE COVID-19: disease, impact & epidemiology overview The virus: SARS-CoV-2 LEARN MORE The disease: COVID-19 LEARN MORE Vaccines to end the current pandemic LEARN MORE Technology platforms for COVID-19 vaccines Technology platforms LEARN MORE mRNA technology LEARN MORE COVID-19 mRNA vaccine (BNT162b2) global development BioNTech SARS-CoV-2 vaccine candidates LEARN MORE Project Lightspeed LEARN MORE Pre-Clinical Development LEARN MORE Phase 1/2 Study: Safety and immunogenicity LEARN MORE Media Introduction to COVID-19 Herd Immunity mRNA Based Vaccines Project Lightspeed COMIRNATY® (COVID-19 mRNA Vaccine) Download Center SmPC DOWNLOAD Read also Meet our leadership team Get to know our partners We offer multiple services Explore our pipeline BNTCom00189 We look forward to connecting with you SEND US A MESSAGE BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 For questions on logistics, handling or other issues: service@biontech.de For any other questions, please use our contact form at connect.biontech.de We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases Footer Main Connect Our DNA How We Translate Science For Patients Investors & Media Careers Footer Manufacturing GmbH 2 Imprint Terms Of Use General Terms And Conditions General Conditions Of Purchase Data Privacy Statement Data Processing Terms Business Partners Adverse Event Reporting Cookie Settings Follow us Open configuration options © Copyright BioNTech Manufacturing GmbH 2021. All Rights Reserved. Cookies are used by us and third parties on our site. For all cookies that are not technically necessary, we require your consent (e.g. cookies for statistical purposes, tracking, analytics, advertising, if necessary configuration). By selecting or deselecting the cookies, you consent to or reject the processing of your personal data (e.g. your IP address) for the respective purpose. You can revoke or give your consent at any time in our Data Privacy Policy under the item "Cookies". Essential Statistics Marketing Performance External Media Personalisation Save preferences ACCEPT ALL COOKIES